Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

2 chapters
Play All
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Justin Gainor, MD
    Program Director, Center for Thoracic Cancers
    Director, Targeted Immunotherapy
    Associate Professor, Medicine at Harvard Medical School
    Massachusetts General Hospital
    Boston, MA 

    Dr. Gainor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research Support: BMS, Merck, AZ, Novartis, Takeda, Beigene, Nextpoint, Palleon
    Ownership Interests: AI Protein
    Consulting Fees: BMS, Genentech/Roche, AZ, Mariana Oncology, Mirati, Nuvalent, Pfizer, Novartis, Merck, ITeos, Karyopharm, Silverback, Amgen, Arcus, Beigene, Jazz, Sanofi, Tempus
    Spouse: Employed at Ironwood Pharmaceuticals

    Jacob Sands, MD 
    Oncologist, Assistant Professor
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, MA 

    Dr. Sands has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research Support: Amgen, Harpoon.
    Consulting Fees: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheimer, Daiichi-Sankyo, G1 Therapeutics, Lilly, Pfizer, Medtronic, Gilead

    Reviewers/Content Planners/Authors:

    • Wilma Guerra has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Individualize therapeutic planning for patients with HER2-altered NSCLC using HER2-targeted ADC therapy.
    • Individualize therapeutic planning for patients with HER2-altered NSCLC and brain metastases using HER2-targeted ADC therapy.
  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 credit AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 8/13/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hours/0.05CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-083-H01-P. This learning activity is knoweldge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Justin Gainor, MD
    Program Director, Center for Thoracic Cancers
    Director, Targeted Immunotherapy
    Associate Professor, Medicine at Harvard Medical School
    Massachusetts General Hospital
    Boston, MA 

    Dr. Gainor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research Support: BMS, Merck, AZ, Novartis, Takeda, Beigene, Nextpoint, Palleon
    Ownership Interests: AI Protein
    Consulting Fees: BMS, Genentech/Roche, AZ, Mariana Oncology, Mirati, Nuvalent, Pfizer, Novartis, Merck, ITeos, Karyopharm, Silverback, Amgen, Arcus, Beigene, Jazz, Sanofi, Tempus
    Spouse: Employed at Ironwood Pharmaceuticals

    Jacob Sands, MD 
    Oncologist, Assistant Professor
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, MA 

    Dr. Sands has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research Support: Amgen, Harpoon.
    Consulting Fees: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheimer, Daiichi-Sankyo, G1 Therapeutics, Lilly, Pfizer, Medtronic, Gilead

    Reviewers/Content Planners/Authors:

    • Wilma Guerra has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Individualize therapeutic planning for patients with HER2-altered NSCLC using HER2-targeted ADC therapy.
    • Individualize therapeutic planning for patients with HER2-altered NSCLC and brain metastases using HER2-targeted ADC therapy.
  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 credit AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 8/13/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hours/0.05CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-083-H01-P. This learning activity is knoweldge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule11 Dec 2024